Kana

Bladder cancer highlights #ASCO26 1) Data for 3 Nectin4/Topo1 ADCs showing efficacy (LY4052031 , LY4101174, SHR-A2102). Can we sequence these drugs after EV? 2) Data from EV302/303 for EVP showing longer term outcomes and QOL 3) adjuvant QOL data for adjuvant pembro (AMBASSADOR) or atezo (IM011) 4) updated data for durvalumab in MIBC (with RT) & NMIBC (POTOMAC). @OncoAlert

ASCO this year has 5,000+ abstracts. But ~24 will actually change practice. Here is that map. Data-grid is the shortest path through ASCO 2026: 12 disease areas, 24 critical readouts, 5 plenaries, and 2 (confirmed) misses already on the board. Few things jump out immediately: ▪️Daraxonrasib gets the headline (13.2 vs 6.7 mo) ▫️Sarcoma gets a plenary as public science funds P3 that pharma would not. ▫️Lung cancer remains crowded: RET adjuvant, bispecific OS, post-osimertinib, next-gen EGFR. ▫️Breast cancer reminds us that not every big swing lands By next week, only a handful of these cells will become new standards of care. This is your cheat sheet to keep that score. - - - - - Source: @asco · @OncLive · @CancerNetwrk · via @Jori_health - - - - -

So, #ASCO26, the benefit is regardless of PDL1. 🤔Maybe the benefit is only because of zanidatamab? 🤔Do we need tislelizumab? 🤔Or because control arm do not have IO? My comment in 01.26👇

#ASCO26 GI cancer-related abstracts, tables 3-5: Table 3. Important negative studies Table 4a and 4b. Novel agents Table 5. Practice re-affirming studies Studies with negative results could be important too! All four negative studies investigated addition of immunotherapy to SOC. For novel agents, I am particularly excited about iza-bren, atebimetinib, and tegavivint, but all data look promising with the limitation of early-phase trials. #GIcancers @OncoAlert @VanMorrisMD @jgong15 @ArndtVogel

⚡️ IMvigor011 at #ASCO26: ctDNA-guided adjuvant atezolizumab in MIBC improved DFS and OS in ctDNA+ patients — with no negative impact on patient-reported QoL. >90% of patients reported little or no treatment side-effect burden throughout therapy. Efficacy and tolerability together. Relevant for shared decision-making in the adjuvant setting. #BladderCancer @OncoBellmunt @ASCO asco.org/abstracts-pres…

🤩 ✅ EU CHMP approval: Cami is beneficial in emerging ESR1 mt resistant disease. Remember also ✴️ 1. Genomic biomarkers will only just get cheaper 💰 2. Oncology already accepts the principle that biochemical or molecular progression occurs prior to clinical PD ie in prostate cancer - why do #breastcancer patients need to show OS benefit? 🥴 3. Precision medicine also provides better health economics 🎓

Prepping for #ASCO26? First time at the conference?? Here's the must have guide to help you savor your time! @PallOncCoP @OncoAlert🚨 #OncoAlertAF @FadiHaddad_MD @Abdallah81MD @Erman_Akkus @bavilima @acampsmalea @DrFMartinelli @Dr_Ivanoncologo @orellanauro @FernandoOnco @Lucarecco @HHorinouchi @ElisaAgostinett @to_be_elizabeth @BRicciutiMD @nataliagandur @GaiaGriguolo @JankovicK @weoncologists @OncoReporte @GIMedOnc @MarioBalsaMD @DrMirallas @OscarTahuahua @DrRishabhOnco @UOzkerim @Onco_Cifu88 @DraMartinezLago @DaisukeKotani @marklewismd @AnaVManana

We built OncoSphere AI: an agentic AI system designed for real multidisciplinary oncology workflows. Not a chatbot. Not a summarizer. An autonomous agent that reasons across guidelines, trial data, imaging, and pathology to support clinical decision-making the way a tumor board actually works. Presenting at #ASCO26 @ASCO: asco.org/abstracts-pres… The oncology AI tools that will matter aren't the ones that answer questions. They're the ones that run workflows navigation, trial matching, treatment sequencing, toxicity guidance, end to end. That's what agentic AI means. That's what we're building!

🟦FIGHT-302 #ASCO26 @ASCO 1L pemigatinib vs gem-cis in advanced BTC with FGFR2 rearrangement ✅1.5mo median PFS benefit 🚨Similar OS, 24.4mo (50% crossover) ⚠️Closed early due to slow accural ✅My takeaway: Patients with FGFR+ should access the drug either in 1 or 2 L Pemigatimib is an option in 1L for patients ineligible for chemo or IO #cancer #biliary #oncology #cholangiocarcinoma #MedX @OncoAlert

Well, I have some news to share. 😊 Very grateful and honoured to my institution and Department for recognizing my contributions through this promotion. It really means a lot. Incredibly thankful and grateful to everyone who has contributed to this journey- my mentors, teachers, students, mentees, colleagues, friends, and patients spanning 4 different countries. Also the funders of my research (OICR, MOHCCN) and organizations like WHO/ASCO/ESMO who opened up doors for me. But most of all, to my family, whose love and sacrifices are the reason I am here today.

#ASCO26 KN-522 final analysis. Median follow-up: 7.8 years. 7-year EFS: 78.3% vs 69.8% HR 0.68 7-year OS: 85.1% vs 77.2% HR 0.64

#ASCO26 has released most abstracts. I will break down GI cancer-related abstracts to five tables: Important studies Interesting studies Important negative studies Novel agents Practice re-affirming studies Abstracts that have not been released but are eagerly anticipated: RASolute-302, EMERALD-3, CIRCULATE (AIO), Episode-3, BREAKWATER update, PUMP. Please see the tables below for the first two tables (important studies, interesting studies). More to come. @OncoAlert @jgong15 #GIcancer

#ASCO26 One of the coolest abstract I’ve seen so far isn’t GI, and its a rapid oral most people have missed. ARCHER: Prophylactic peptide targeting ALK resistance mutations in advanced ALK+ NSCLC Abstract #: 8517 Presentation: Rapid Orals Lung, May 30 The usual cancer playbook is: Develop therapy → give therapy → resistance emerges → next therapy → repeat. ARCHER presents alternative pathway: What if we could short-circuit resistance before it happens? This is a new playbook altogether. In oncology, that usually runs into the brick wall of cumulative toxicity. But immune interception against predictable resistance mutations may be a way around that. Also, can we please stop calling these “vaccines”? Yes, I know they technically are vaccines. But I also know how many patients hear that word and immediately shut down. Quick hits: 📌 Phase 1b, first-in-human 15 patients with advanced ALK+ NSCLC All without progression on standard ALK TKI 🧬 Targeted 7 common ALK resistance mutations 💊 Patients continued their ALK TKI Alectinib: 47% Lorlatinib: 33% Brigatinib: 20% 🧫 Immune response seen T cell responses in 10/14 evaluable patients Median 12-fold increase Responses included key resistance mutations ✅ Safety was as excpted Mostly grade 1 TRAEs 📈 Disease control 93% at median follow-up 11.5 months One fascinating detail: the single patient with oligoprogression after robust immune response developed KRAS G12D without a detectable ALK resistance mutation. This is not a normal mutation pattern in ALK+ disease. That is exactly the kind of biologic signal that makes this so interesting. Similar efforts are ongoing in CRC and Panc (IE Elicio Therapeutics) Early with a tiny N. BUT, this is such a important idea and worth highlighting. Don’t wait for resistance. Anticipate it. Intercept it. Force the tumor down a different path. If I had millions of dollars in development money, I'd be throwing it at this idea. @TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO

Only few days to #ASCO26. For breast oncologists, this edition will deliver a new promising biomarker to spare unnecessary chemo, informative updates from practice-changing trials across subtypes, and major innovations coming from China. See you in Chicago next week! #bcsm

Yesterday I had a talk on use of social media by Oncologist at ICON conference ( national oncology conference in India 🇮🇳 ) .Sharing some of the slides . May be useful for all , especially before asco 2026 🙂 @oncology_bg @ErikaHamilton9 @dr_yakupergun @oncodaily

🟧Gastric/gastroesophageal oral abstracts #ASCO26 @ASCO #cancer #oncology #MedX #GI #gastrointestinal #gastric #esophageal @OncoAlert

🇨🇳 DRAGON-01 ✔️ Phase III: IP+IV paclitaxel + S-1 vs IV paclitaxel + S-1 in GC with peritoneal metastases 📈 improved mOS: 19.4 vs 13.9 months and mPFS: 11.2 vs 7.2 months ⚠️ No increase in grade 3–4 toxicity 💡 IP therapy gains stronger evidence in GC peritoneal disease 🔗 doi.org/10.1001/jamaon… @OncoAlert

#ASCO26 abstr 3510 Onvansertib + Chemo + Bev in 1L RAS-mutated mCRC (rPh2 CRDF-004 trial) 💡Onvansertib: PLK1 inhibitor ◾️ORR: 72.2% vs 43.2% ◾️PFS: NR vs 10.97 mo (HR 0.37, p = 0.048) 👉Promising results! A Ph3 is warranted. @ASCO @OncoAlert

#ASCO26 abstr 3512 Ph3 CR-SEQUENCE: FOLFOX + Pani ➡️ FOLFIRI + Bev (SEQ1) vs FOLFOX + Bev ➡️ FOLFIRI + Pani (SEQ2) in 1L RAS wt left-sided mCRC ◾️ORR: 80.95 vs 54.25% (p<0.01) ◾️PFS1: 14.09 vs 12.39 mo (P=0.03) ◾️OS: 36.57 vs 31.74 mo (p=0.2949) 👉SEQ1 showed a significant PFS benefit with 1L anti-EGFR over Bev — a finding distinct from prior pivotal trials. OS difference was not significant, though a trend favored SEQ1. Awaiting the full presentation for confirmation. @ASCO @OncoAlert

Key upper GI & hepatobiliary studies from hashtag#ASCO26 — a quick summary of what stood out across HCC, gastric, esophageal, pancreatic, and biliary cancers. From locoregional combinations to novel T-cell engagers and ctDNA-driven biomarkers, this was a data-rich session.